Telemedicine Home-based Management in Patients With CHF and Type 2 Diabetes
- Conditions
- Chronic Heart FailureDiabetes Mellitus
- Interventions
- Other: TeleassistanceOther: Quality of lifeOther: Biochemistry evaluationOther: TeleconsultationOther: TelerehabilitationOther: TelemonitoringOther: mHealthOther: telepsycologyOther: Clinical evaluationOther: State of health of the patient
- Registration Number
- NCT05633784
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Brief Summary
The progressive ageing of the population of industrialized countries is accompanied by a dramatic increase in the prevalence of chronic multi-pathologies. In the general population, HF is associated with a higher prevalence of T2DM compared with patients without HF and with marked regional differences observed in Europe and the rest of the world. In clinical trials of chronic HF patients, the prevalence of T2DM is approximately 30% in patients with reduced or preserved ejection fraction and rises to as much as 45% in hospitalized patient registries. A complex drug regimen is often associated with low adherence in patients with HF and T2DM and poor adherence is associated with adverse clinical events. Similarly, adherence to recommendations regarding lifestyle changes, such as increasing physical activity, is often limited despite these changes' favourable effects on the patient. Therefore, interventions are needed to improve all these factors and optimize adherence. The inclusion of telemedicine (telenursing, telerehabilitation, mHealth) focused on health and correct behaviour can create opportunities to implement customized and scalable solutions in populations at risk. The project will aim to evaluate for patients with chronic diseases with a complex phenotype (heart failure and type II diabetes mellitus) the effectiveness of a remote surveillance program with particular attention to lifestyle changes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 163
- Inform consent
- Age ≥ 18 years
- Documented diagnosis of heart failure, NYHA class II-III (reduced or preserved Ejection fraction without hospitalization in the last 3 months
- Diagnosis of Diabetes Mellitus Type II in pharmacological treatment from at least one month
- Ability to walk without assistive devices
- Consent to using a device (independently or with the support of a caregiver) for recording the single electrocardiographic trace at home
- Consent to using the App
- Subjects with poor collaboration
- No possibility of using mobile technology
- Life expectancy of fewer than 6 months
- Medical issues that preclude participation in the program
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intervention group Teleassistance At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group mHealth At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group State of health of the patient At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Control group Biochemistry evaluation At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP. Intervention group Teleconsultation At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group telepsycology At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Control group State of health of the patient At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP. Intervention group Telerehabilitation At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group Biochemistry evaluation At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group Clinical evaluation At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Control group Quality of life At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP. Intervention group Telemonitoring At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Intervention group Quality of life At the beginning and at the end of the 6-month study period, patients of the Intervention group will perform outpatient cardiological visits. During the 6-month they will be followed through a home remote teleassistance program, designed to provide multidisciplinary support. Control group Clinical evaluation At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
- Primary Outcome Measures
Name Time Method Change in tolerance capacity Baseline and 6 months The change from baseline in tolerance capacity will be measured by walking test performance (meters walked).
- Secondary Outcome Measures
Name Time Method Change of hospitalizations 6 months Change of hospitalizations for cardiovascular problems, diabetes and all-causes
Number of Steps Baseline and 6 months The difference in the weekly mean in the number of steps from baseline over the 6 months of follow-up.
Change in quality of life related to Diabetes Baseline and 6 months Change in quality of life measured by Diabetes quality of life (DQoL) questionnaire
Change in quality of life Baseline and 6 months Change in quality of life measured by 12-item Short Form Survey (SF-12) questionnaire
Assessment of physical activity. Baseline and 6 months Change in physical activity profile by Physical Activity Scale for the Elderly (PASE).
The total PASE score is computed by multiplying the amount of time spent on each activity (hours/week) or participation (yes/no) in an activity by the empirically derived item weights and summing overall activities.Change in quality of life related to heart failure Baseline and 6 months Change in quality of life measured by Minnesota Living with Heart Failure (MLHFQ) questionnaire
HbA1c dosage Baseline and 6 months Change of the disease status
Trial Locations
- Locations (3)
Azienda Ospedaliera Bolognini di Seriate Bergamo
🇮🇹Seriate, Bergamo, Italy
Istituti Clinici Scientifici Maugeri
🇮🇹Lumezzane, Brescia, Italy
Papa Giovanni XXIII Hospital
🇮🇹Bergamo, Italy